CV Sciences Inc (OTCMKTS:CVSI) Launches on Expanding Footprint

CV Sciences Inc (OTCMKTS:CVSI) Launches on Expanding Footprint

SHARE

The CV Sciences Inc (OTCMKTS:CVSI) rocket continues to launch higher as data and sentiment mix with a big board listing possibility to ignite the story. The stock has ramped as much as 75% in the past few weeks, with volume increasing as the price per share moves higher, suggesting that the total dollar involvement is skyrocketing right now. One of the drivers is the company’s massive expansion in distribution footprint for its CBD segment.

As a case in point, the company recently announced that its flagship brand, PlusCBD Oil, continues to expand its distribution in the natural, healthy, and organic industry. According to the release, “The Company today announced that its brand of #1 selling hemp CBD products (according to SPINS scan data) are currently available in 1968 natural and organic health food stores as of June 30, 2018. This represents an 11.1% sequential increase over the Company’s retail store count as of March 31, 2018.”

CV Sciences Inc (OTCMKTS:CVSI) frames itself as a life science company, focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD).

CVSI operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Following the CanX Acquisition in December 2015, CV Sciences commenced its preclinical drug development program during the second quarter of 2016. The Company’s drug development efforts include pursuing synthetic-based Cannabidiol drug candidates in areas that have the potential to provide significant improvements in therapeutic patient treatments with sizable addressable markets.

The company was formerly known as CannaVEST Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.

CV Sciences Inc is led by Michael J. Mona, JR. founder of CV Sciences, Mr. Mona possesses over 30 years of senior management experience in a range of industries including real estate/construction, industrial farming, chemical processing and consumer products. Mr. Mona is a recognized industry leader in hemp farming operations and chemical extraction and has established a global supply chain of hemp-derived products.

According to company materials, “CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.”

Find out when $CVSI stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Traders will note 74% during the past month in terms of shareholder gains in the name. In addition, the name has benefitted from a jump in recent trading volume to the tune of 57% over what the stock has registered over the longer term.

“We continue to expand distribution in the natural/organic health food store sales channel with an 11.1% increase in store count when compared to Q1 2018,” stated Joseph Dowling, Chief Executive Officer at CV Sciences.  “Our retail channel expansion, along with increased industry forecasts of hemp CBD products, are positive indicators for Company growth.”

Now commanding a market cap of $303.4M, CVSI has a significant war chest ($7.2M) of cash on the books, which is balanced by about $867K in total current liabilities. CVSI is pulling in trailing 12-month revenues of $33.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 202.5%. We will update the story again soon as developments transpire. Sign-up for continuing coverage on shares of $CVSI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CVSI, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter